Actas Dermo-Sifiliográficas (English Edition) Actas Dermo-Sifiliográficas (English Edition)
Actas Dermosifiliogr 2018;109:312-22 - Vol. 109 Num.4 DOI: 10.1016/j.adengl.2018.03.011
Morphea in Childhood: An Update
Morfea en la infancia: actualización
B. Aranegui, , J. Jiménez-Reyes
Servicio de Dermatología, Hospital Universitario Infanta Cristina , Parla, Madrid, Spain
Received 22 January 2017, Accepted 25 June 2017

Morphea is an inflammatory, fibrosing skin disorder. When it occurs in childhood, it is also known as juvenile localized scleroderma. It is more common in girls and typically appears around the age of 5 to 7 years. According to a recent classification system, morphea is divided into 5 types: circumscribed (plaque), linear, generalized, pansclerotic, and mixed. Approximately 40% of patients present extracutaneous manifestations. Childhood morphea is treated with phototherapy, oral or topical calcitriol, topical tacrolimus 0.1%, methotrexate, topical or systemic corticosteroids, mycophenolate mofetil, bosentán, and topical imiquimod 5%. A variety of measuring tools are used to monitor response to treatment. Few prognostic studies have been conducted, but findings to date suggest that the disease tends to run a chronic or intermittent-recurrent course and frequently causes sequelae.


La morfea es una enfermedad de la piel que se manifiesta en forma de inflamación y fibrosis. En niños y jóvenes, también se conoce como esclerodermia juvenil localizada. En edad infantil, afecta con mayor frecuencia al sexo femenino y la edad de comienzo se ha establecido en torno a los 5-7 años. Una clasificación reciente divide la morfea en: circunscrita (en placas), lineal, generalizada, panesclerótica y mixta. Alrededor de un 40% de los pacientes presentan manifestaciones extracutáneas.

Los tratamientos empleados en morfea infantil son: fototerapia, calcitriol oral, calcipotriol tópico, tacrolimus 0,1% tópico, metotrexato, glucocorticoides tópicos y sistémicos, mofetil micofenolato, bosentán e imiquimod 5% tópico. Diversas medidas de resultado pueden ayudar a monitorizar el tratamiento. Los estudios pronósticos son escasos, pero apuntan hacia una enfermedad con tendencia a un curso crónico o intermitente-recurrente y una frecuencia considerable de secuelas.

Morphea, Childhood, Localized juvenile scleroderma, Linear scleroderma, Facial hemiatrophy, Review literature as topic, Phototherapy, Methotrexate
Palabras clave
Morfea, Infancia, Esclerodermia juvenil localizada, Esclerodermia lineal, Hemiatrofia facial, Revisión narrativa, Fototerapia, Metotrexato


To access the full text of the publication Actas Dermo-Sifiliográficas you need to be a subscriber or member of the Academia Española de Dermatología y Venereología.

  • If you are a member of the Academia Española de Dermatología y Venereología::

    • If this is your first time in the Web:
      You can get your login by contacting Elsevier Spain in: or through the customer service phone 902 88 87 40 through the customer service phone 902 88 87 40.

      Calling from Spain
      902 88 87 40 (from 9 to 18 h)
      Calling from outside Spain
      +34 932 418 800 (from 9 to 18 h)

  • If you are a subscriber:
    Can you recover your data in the "I Forgot my Password" button on the right sidebar of this website.

Actas Dermosifiliogr 2018;109:312-22 - Vol. 109 Num.4 DOI: 10.1016/j.adengl.2018.03.011
Cookies Policy
To improve our services and products, we use cookies (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here.